280 related articles for article (PubMed ID: 28763236)
1. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human lactoferrin-Fc fusion with an improved plasma half-life.
Shiga Y; Oshima Y; Kojima Y; Sugimoto A; Tamaki N; Murata D; Takeuchi T; Sato A
Eur J Pharm Sci; 2015 Jan; 67():136-143. PubMed ID: 25433245
[TBL] [Abstract][Full Text] [Related]
3. Improved Refolding of a Human IgG1 Fc (CH2-CH3) Scaffold from Its Inclusion Body in E. coli by Alkaline Solubilization.
Ishikawa S; Ishikawa H; Sato A
Biol Pharm Bull; 2022; 45(3):284-291. PubMed ID: 35228394
[TBL] [Abstract][Full Text] [Related]
4. Albumin fusion at the N-terminus or C-terminus of human lactoferrin leads to improved pharmacokinetics and anti-proliferative effects on cancer cell lines.
Ueda K; Shimizu M; Ohashi A; Murata D; Suzuki T; Kobayashi N; Baba J; Takeuchi T; Shiga Y; Nakamura M; Kagaya S; Sato A
Eur J Pharm Sci; 2020 Dec; 155():105551. PubMed ID: 32946958
[TBL] [Abstract][Full Text] [Related]
5. IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Teplyakov A; Zhao Y; Malia TJ; Obmolova G; Gilliland GL
Mol Immunol; 2013 Nov; 56(1-2):131-9. PubMed ID: 23628091
[TBL] [Abstract][Full Text] [Related]
6. Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO/dhfr- cells.
Cao M; Cao P; Yan H; Lu W; Ren F; Hu Y; Zhang S
Appl Biochem Biotechnol; 2009 Jun; 157(3):562-74. PubMed ID: 19099209
[TBL] [Abstract][Full Text] [Related]
7. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
8. Evidence that the hinge region plays a role in maintaining serum levels of the murine IgG1 molecule.
Kim JK; Tsen MF; Ghetie V; Ward ES
Mol Immunol; 1995 May; 32(7):467-75. PubMed ID: 7783750
[TBL] [Abstract][Full Text] [Related]
9. The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte receptors Fc gamma RI and Fc gamma RIIa bind to a region in the Fc distinct from that recognized by neonatal FcR and protein A.
Wines BD; Powell MS; Parren PW; Barnes N; Hogarth PM
J Immunol; 2000 May; 164(10):5313-8. PubMed ID: 10799893
[TBL] [Abstract][Full Text] [Related]
10. Catabolism of the murine IgG1 molecule: evidence that both CH2-CH3 domain interfaces are required for persistence of IgG1 in the circulation of mice.
Kim JK; Tsen MF; Ghetie V; Ward ES
Scand J Immunol; 1994 Oct; 40(4):457-65. PubMed ID: 7939418
[TBL] [Abstract][Full Text] [Related]
11. [Expression of ATR-Fc fusion protein in CHO cells].
Gao LH; Hu XW; Chen W; Xu JJ; Zhao J; Chen HP
Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):826-31. PubMed ID: 16285529
[TBL] [Abstract][Full Text] [Related]
12. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis.
Kim JK; Tsen MF; Ghetie V; Ward ES
Eur J Immunol; 1994 Mar; 24(3):542-8. PubMed ID: 8125126
[TBL] [Abstract][Full Text] [Related]
13. Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor.
Kim JK; Tsen MF; Ghetie V; Ward ES
Eur J Immunol; 1994 Oct; 24(10):2429-34. PubMed ID: 7925571
[TBL] [Abstract][Full Text] [Related]
14. Structural consequences of aglycosylated IgG Fc variants evolved for FcγRI binding.
Ju MS; Na JH; Yu YG; Kim JY; Jeong C; Jung ST
Mol Immunol; 2015 Oct; 67(2 Pt B):350-6. PubMed ID: 26153451
[TBL] [Abstract][Full Text] [Related]
15. Generation and Characterization of an IgG4 Monomeric Fc Platform.
Shan L; Colazet M; Rosenthal KL; Yu XQ; Bee JS; Ferguson A; Damschroder MM; Wu H; Dall'Acqua WF; Tsui P; Oganesyan V
PLoS One; 2016; 11(8):e0160345. PubMed ID: 27479095
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment.
Zeng F; Yang C; Gao X; Li X; Zhang Z; Gong R
J Biol Chem; 2018 Dec; 293(49):19127-19135. PubMed ID: 30327432
[TBL] [Abstract][Full Text] [Related]
17. Binding activity difference of anti-CD20 scFv-Fc fusion protein derived from variable domain exchange.
Geng SS; Feng J; Li Y; Sun Y; Gu X; Huang Y; Wang Y; Kang X; Chang H; Shen B
Cell Mol Immunol; 2006 Dec; 3(6):439-43. PubMed ID: 17257497
[TBL] [Abstract][Full Text] [Related]
18. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells.
Wright A; Morrison SL
J Immunol; 1998 Apr; 160(7):3393-402. PubMed ID: 9531299
[TBL] [Abstract][Full Text] [Related]
19. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein.
Lee JH; Cho JH; Yeo J; Lee SH; Yang SH; Sung YC; Kang JH; Park CS
Biologicals; 2013 Mar; 41(2):77-83. PubMed ID: 23190454
[TBL] [Abstract][Full Text] [Related]
20. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
